Sohini Das

HR experts say important to monitor progress of upskilling schemes; existing partnerships with industry need to be strengthened

Between April-July 2024, 125cc segment sees 21 per cent growth against 46.5% of 125-150cc segment

An industry expert pointed out that Chinese companies typically resort to predatory pricing whenever API production increases in India

Maruti Suzuki India (MSIL) is planning a new channel called Arena Satellites, targeting smaller towns and newer markets, a senior company official said.

GST cut for cancer drugs: Move is part of ongoing initiatives to reduce financial burden for cancer patients

Based on industry data, the average discounts by the top 13 players in 2023 were Rs 34,630, which increased to Rs 38,816 so far in 2024. According to data shared by Jato Dynamics, Toyota and Honda are the two companies that have more than doubled their discounts so far in 2024 (See Chart I). The average discounts by Toyota jumped 140 per cent to Rs 49,914 this year, compared to Rs 20,795 in 2023. Similarly, Honda saw a 120 per cent rise in discounts during the same period from Rs 15,412 to Rs 33,930.

Priced at Rs 7.99 lakh for the entry-level product, M&M has launched the diesel and CNG variants of Veero, and an electric version will come in the future.

India's second-largest passenger vehicles firm will be valued at Rs 1.59 trillion at the top-end of the price band of Rs 1,865-Rs 1,960.

Indian pharmaceutical companies are stepping up their efforts to combat the problem of counterfeit drugs, employing a variety of strategies, from packaging innovations to engaging private investigation agencies.The stakes are high, as counterfeit medicines not only harm consumers but also tarnish the reputation of leading brands.

Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points.Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y).Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.